NCT02511431View on ClinicalTrials.gov

Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 29, 2015

Primary Completion Date

February 23, 2017

Study Completion Date

February 23, 2017

Conditions
Hepatitis D
Interventions
DRUG

Lonafarnib

prenylation inhibitor to be administered daily at doses of 50 mg, 75 mg or 100 mg.

DRUG

Ritonavir

FDA approved drug for use of boosting other drugs. Will be used to boost Lonafarnib as they both use the same cytochrome P450 system. Will be administered at 100 mg daily.

OTHER

Placebo

Placebo

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT02511431 - Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir | Biotech Hunter | Biotech Hunter